Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed
Executive Summary
The US FDA’s capacity planning formula indicates a smaller biosimilar program than a year ago, but says supplement, meeting and other work continue to increase.
You may also be interested in...
US FDA User Fee Staffing: The Objective Capacity Planning Adjuster Often Needs Subjective Review
The FDA has overruled the results from its own formula intended to match resource levels with workload every time except once.
GDUFA III Agreement Will Constrain Fee Revenue Increases
Generic user fee program's next iteration will also offer improved mid- and post-assessment communications for sponsors to receive feedback from US FDA.
GDUFA III Agreement Will Constrain Fee Revenue Increases
Generic user fee program's next iteration will also offer improved mid- and post-assessment communications for sponsors to receive feedback from US FDA.